Osteoporosis and Menopause

From a Western perspective, menopause precipitates a sharp decline in circulating estradiol, removing an essential brake on osteoclast activity. Molecularly, estrogen deficiency upregulates RANKL and inflammatory mediators and downregulates osteoprotegerin, favoring bone resorption over formation. This accelerates trabecular deterioration and cortical porosity, particularly at the spine and hip, and explains the surge in vertebral and hip fractures in the decades after menopause. Clinical strategy begins with risk assessment. USPSTF recommends DXA for all women aged 65 and older and for younger postmenopausal women with elevated 10‑year fracture risk by FRAX. Lifestyle foundations—weight-bearing and resistance training, balance work, adequate protein, calcium (~1,200 mg/day total) and vitamin D (800–1,000 IU/day), smoking cessation, and alcohol moderation—are universally advised and reduce both skeletal and fall risks. For symptomatic menopausal women, menopausal hormone therapy (estrogen with progestogen if the uterus is intact; estrogen alone post-hysterectomy) is the most effective treatment for vasomotor and genitourinary symptoms and confers meaningful bone protection when started within 10 years of menopause, though it requires individualized risk–benefit assessment (VTE, stroke, breast cancer). When fracture risk is high or osteoporosis is established, antiresorptives (bisphosphonates, denosumab) and anabolic/dual-acting agents (teriparatide, abaloparatide, romosozumab) provide proven fracture risk reduction. Calcium/vitamin D alone are insufficient for fracture prevention in most community-dwelling women but are important adjuncts—especially alongside medications and in those with low intake or deficiency.

Eastern traditions, especially TCM, conceptualize menopause as a natural waning of Kidney essence (Jing). Because Kidney is said to govern bones and marrow, this constitutional shift manifests as bone weakness and increased susceptibility to fractures. Treatment focuses on restoring balance—tonifying Kidney and Liver, nourishing yin or yang depending on presentation, and moving blood to support tissue repair. In practice, pattern-based herbal formulas (e.g., Liu Wei Di Huang Wan for yin deficiency; You Gui Wan or Zuo Gui Wan for yang/yin deficiency) may be combined with bone-strengthening herbs like Epimedium (Yin Yang Huo) and Eucommia (Du Zhong). Acupuncture protocols often include KI3, BL23, GB39, and SP6 to support Kidney and marrow, with moxibustion in cold/yang-deficient patterns. Tai chi and qigong are frequently prescribed to cultivate balance and strength, reducing fall risk while easing stress and sleep issues common in menopause. Modern studies suggest some of these approaches can modestly improve BMD or symptom scores, but trials are small and heterogeneous, with variable controls. Accordingly, TCM is best framed as complementary to evidence-based screening, nutrition, and pharmacotherapy when indicated. Safety and quality are paramount: use qualified practitioners, review potential herb–drug interactions (e.g., with anticoagulants or thyroid medications), and monitor outcomes (DXA, labs) within an integrative care plan.